

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

“GABAPENTIN CAPSULES” OBTAINS DRUG REGISTRATION APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the “Gabapentin Capsules (0.1g, 0.3g, 0.4g)” (the “**Product**”) developed by CSPC Ouyi Pharmaceutical Co., Ltd.* (石藥集團歐意藥業有限公司), a subsidiary of the Company, has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency of quality and efficacy evaluation of generic drugs.

The mechanisms by which gabapentin produces its analgesic and antiepileptic actions may be related to its structural similarity to the neurotransmitter gamma-aminobutyric acid (GABA), and its therapeutic effects may be produced through the binding to the $\alpha 2\delta$ subunit of voltage-activated calcium channels. The Product is indicated for (i) the treatment of postherpetic neuralgia in adults; and (ii) the adjunctive therapy in the treatment of partial onset seizures, with or without secondary generalization, in adults and children older than 12 years of age; the adjunctive therapy in the treatment of partial onset seizures in children 3 to 12 years of age.

The approval of the Product will further enrich the Group’s product portfolio for nervous system diseases.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 11 July 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. WU Guizhen as independent non-executive directors.

** For identification purposes only*